ArticleCurrent genomics2015
Management of Incidental Findings in the Era of Next-generation Sequencing.
Article in Current genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- The full spectrum of ethical issues in pediatric genome-wide sequencing: a systematic qualitative review.BMC pediatrics · 2021Pooled it
- Precision Medicine in Hematologic Malignancies: Evolving Concepts and Clinical Applications.Biomedicines · 2025Review
- Evolution of genome diagnostics in epidermolysis bullosa: Unveiling the power of next-generation sequencing.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Observational
- Molecular mechanisms of human overgrowth and use ofFrontiers in genetics · 2024Review
- Maternal Effect Mutations: A Novel Cause for Human Reproductive Failure.Geburtshilfe und Frauenheilkunde · 2021Article
- Leveraging Genetics for Hereditary Angioedema: A Road Map to Precision Medicine.Clinical reviews in allergy & immunology · 2021Review
- Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice.Frontiers in pharmacology · 2021Review
- New Frontiers and Old Challenges: How to Manage Incidental Findings When Forensic Diagnosis Goes Beyond.Diagnostics (Basel, Switzerland) · 2020Article
- Article
- Comparing preferences for return of genome sequencing results assessed with rating and ranking items.Journal of genetic counseling · 2020Article
- Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.BMC cancer · 2019Article
- Validation of Ion TorrentGenes · 2018Article
- Implementation of personalized medicine in Central-Eastern Europe: pitfalls and potentials based on citizen's attitude.The EPMA journal · 2018Article
- Single-cell sequencing and tumorigenesis: improved understanding of tumor evolution and metastasis.Clinical and translational medicine · 2017Review
- Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney international · 2017Article
- Comprehensive genetic testing approach for major inherited kidney diseases, using next-generation sequencing with a custom panel.Clinical and experimental nephrology · 2017Article
- Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.Journal of translational medicine · 2017Article
- Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.Gynecologic oncology research and practice · 2017Review
- DECIDE: a Decision Support Tool to Facilitate Parents' Choices Regarding Genome-Wide Sequencing.Journal of genetic counseling · 2016Article
- Defining the Clinical Value of a Genomic Diagnosis in the Era of Next-Generation Sequencing.Annual review of genomics and human genetics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Next-generation sequencing (NGS) technologies allow for the generation of whole exome or whole genome sequencing data, which can be used to identify novel genetic alterations associated with defined phenotypes or to expedite discovery of functional variants for improved patient care. Because this robust technology has the ability to identify all mutations within a genome, incidental findings (IF)- genetic alterations associated with conditions or diseases unrelated to the patient's present condition for which current tests are being performed- may have important clinical ramifications. The current debate among genetic scientists and clinicians focuses on the following questions: 1) should any IF be disclosed to patients, and 2) which IF should be disclosed - actionable mutations, variants of unknown significance, or all IF? Policies for disclosure of IF are being developed for when and how to convey these findings and whether adults, minors, or individuals unable to provide consent have the right to refuse receipt of IF. In this review, we detail current NGS technology platforms, discuss pressing issues regarding disclosure of IF, and how IF are currently being handled in prenatal, pediatric, and adult patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.